Logo image of MXCT

MAXCYTE INC (MXCT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MXCT - US57777K1060 - Common Stock

1.55 USD
-0.08 (-4.91%)
Last: 12/23/2025, 8:23:18 PM
1.58 USD
+0.03 (+1.94%)
After Hours: 12/23/2025, 8:23:18 PM
Fundamental Rating

3

MXCT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. While MXCT has a great health rating, there are worries on its profitability. While showing a medium growth rate, MXCT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MXCT has reported negative net income.
MXCT had a negative operating cash flow in the past year.
MXCT had negative earnings in each of the past 5 years.
In the past 5 years MXCT always reported negative operating cash flow.
MXCT Yearly Net Income VS EBIT VS OCF VS FCFMXCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

With a Return On Assets value of -20.37%, MXCT is not doing good in the industry: 64.91% of the companies in the same industry are doing better.
MXCT has a Return On Equity (-23.47%) which is in line with its industry peers.
Industry RankSector Rank
ROA -20.37%
ROE -23.47%
ROIC N/A
ROA(3y)-13.17%
ROA(5y)-13.81%
ROE(3y)-15.17%
ROE(5y)-17.68%
ROIC(3y)N/A
ROIC(5y)N/A
MXCT Yearly ROA, ROE, ROICMXCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

MXCT has a better Gross Margin (79.79%) than 100.00% of its industry peers.
MXCT's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for MXCT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 79.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.94%
GM growth 5Y-1.59%
MXCT Yearly Profit, Operating, Gross MarginsMXCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

7

2. Health

2.1 Basic Checks

MXCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MXCT has been increased compared to 1 year ago.
Compared to 5 years ago, MXCT has more shares outstanding
MXCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MXCT Yearly Shares OutstandingMXCT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
MXCT Yearly Total Debt VS Total AssetsMXCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 2.16 indicates that MXCT is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.16, MXCT is in line with its industry, outperforming 52.63% of the companies in the same industry.
MXCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.16
ROIC/WACCN/A
WACC10.87%
MXCT Yearly LT Debt VS Equity VS FCFMXCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M 250M

2.3 Liquidity

MXCT has a Current Ratio of 12.39. This indicates that MXCT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of MXCT (12.39) is better than 94.74% of its industry peers.
A Quick Ratio of 11.71 indicates that MXCT has no problem at all paying its short term obligations.
MXCT has a Quick ratio of 11.71. This is amongst the best in the industry. MXCT outperforms 94.74% of its industry peers.
Industry RankSector Rank
Current Ratio 12.39
Quick Ratio 11.71
MXCT Yearly Current Assets VS Current LiabilitesMXCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for MXCT have decreased strongly by -20.59% in the last year.
The Revenue has decreased by -6.44% in the past year.
The Revenue has been growing by 12.31% on average over the past years. This is quite good.
EPS 1Y (TTM)-20.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
Revenue 1Y (TTM)-6.44%
Revenue growth 3Y4.46%
Revenue growth 5Y12.31%
Sales Q2Q%-16.35%

3.2 Future

The Earnings Per Share is expected to grow by 11.36% on average over the next years. This is quite good.
The Revenue is expected to grow by 20.40% on average over the next years. This is a very strong growth
EPS Next Y-4.09%
EPS Next 2Y14.13%
EPS Next 3Y13.66%
EPS Next 5Y11.36%
Revenue Next Year-6.11%
Revenue Next 2Y1.95%
Revenue Next 3Y9.01%
Revenue Next 5Y20.4%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MXCT Yearly Revenue VS EstimatesMXCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
MXCT Yearly EPS VS EstimatesMXCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MXCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MXCT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MXCT Price Earnings VS Forward Price EarningsMXCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MXCT Per share dataMXCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as MXCT's earnings are expected to grow with 13.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.13%
EPS Next 3Y13.66%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MXCT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

MAXCYTE INC

NASDAQ:MXCT (12/23/2025, 8:23:18 PM)

After market: 1.58 +0.03 (+1.94%)

1.55

-0.08 (-4.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-02 2026-03-02/amc
Inst Owners70.79%
Inst Owner Change-5.07%
Ins Owners1.32%
Ins Owner Change2.81%
Market Cap165.34M
Revenue(TTM)38.63M
Net Income(TTM)-44.77M
Analysts83.08
Price Target6.47 (317.42%)
Short Float %2.83%
Short Ratio2.85
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.61%
Min EPS beat(2)-13.86%
Max EPS beat(2)6.63%
EPS beat(4)3
Avg EPS beat(4)6.24%
Min EPS beat(4)-13.86%
Max EPS beat(4)19.64%
EPS beat(8)6
Avg EPS beat(8)14.2%
EPS beat(12)9
Avg EPS beat(12)14.45%
EPS beat(16)13
Avg EPS beat(16)16.81%
Revenue beat(2)1
Avg Revenue beat(2)-3.6%
Min Revenue beat(2)-12.47%
Max Revenue beat(2)5.28%
Revenue beat(4)3
Avg Revenue beat(4)2.21%
Min Revenue beat(4)-12.47%
Max Revenue beat(4)8.53%
Revenue beat(8)6
Avg Revenue beat(8)11.35%
Revenue beat(12)8
Avg Revenue beat(12)5.7%
Revenue beat(16)12
Avg Revenue beat(16)9.06%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.51%
EPS NY rev (1m)6.72%
EPS NY rev (3m)5.98%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-2.3%
Revenue NY rev (3m)-2.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.62
P/FCF N/A
P/OCF N/A
P/B 0.87
P/tB 0.89
EV/EBITDA N/A
EPS(TTM)-0.41
EYN/A
EPS(NY)-0.27
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0.34
BVpS1.79
TBVpS1.75
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.37%
ROE -23.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 79.79%
FCFM N/A
ROA(3y)-13.17%
ROA(5y)-13.81%
ROE(3y)-15.17%
ROE(5y)-17.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.94%
GM growth 5Y-1.59%
F-Score2
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 41.44%
Cap/Sales 5.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.39
Quick Ratio 11.71
Altman-Z 2.16
F-Score2
WACC10.87%
ROIC/WACCN/A
Cap/Depr(3y)270.47%
Cap/Depr(5y)255.66%
Cap/Sales(3y)18.33%
Cap/Sales(5y)14.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
EPS Next Y-4.09%
EPS Next 2Y14.13%
EPS Next 3Y13.66%
EPS Next 5Y11.36%
Revenue 1Y (TTM)-6.44%
Revenue growth 3Y4.46%
Revenue growth 5Y12.31%
Sales Q2Q%-16.35%
Revenue Next Year-6.11%
Revenue Next 2Y1.95%
Revenue Next 3Y9.01%
Revenue Next 5Y20.4%
EBIT growth 1Y-13.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year37.57%
EBIT Next 3Y15.85%
EBIT Next 5Y12.68%
FCF growth 1Y-11.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-38.01%
OCF growth 3YN/A
OCF growth 5YN/A

MAXCYTE INC / MXCT FAQ

What is the fundamental rating for MXCT stock?

ChartMill assigns a fundamental rating of 3 / 10 to MXCT.


What is the valuation status of MAXCYTE INC (MXCT) stock?

ChartMill assigns a valuation rating of 0 / 10 to MAXCYTE INC (MXCT). This can be considered as Overvalued.


How profitable is MAXCYTE INC (MXCT) stock?

MAXCYTE INC (MXCT) has a profitability rating of 1 / 10.


What is the financial health of MAXCYTE INC (MXCT) stock?

The financial health rating of MAXCYTE INC (MXCT) is 7 / 10.